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EFFICACY OF IMMUNIZATION AGAINST HEPATITIS B VIRUS INFECTION
IN ACUTE LYMPHOBLASTIC LEUKEMIA
V.R. Prasanth, Binitha Rajeswari, T. Priyakumary, Parukuttyamma
Kusumakumary. Division of Pediatric Oncology, Regional Cancer Centre,
Thiruvananthapuram, India
Introduction: Children with malignant disease are at an especially high
risk for developing hepatitis B virus infection from immunosuppression
secondary to chemotherapy, radiotherapy andmultiple blood transfusions.
Most of the children infected with HBV develop chronic hepatitis. The
increasing potential for the cure of childhood malignant diseases em-
phasizes the need for a method of reducing hepatitis and its sequelae in
these children.
Objective: The aim of the study was to assess whether immunization
against Hepatitis B (Hepatitis B vaccination +/- Hepatitis B Immunoglob-
ulin) prior to start of chemotherapy provides protective anti HBs titer in
patients with Acute Lymphoblastic Leukemia.
Materials and Methods: This observational study included 104 consecu-
tive children with Acute Lymphoblastic Leukemia treated in Paediatric
Oncology Division, Regional Cancer Centre, Thiruvanathapuram and on
follow up after completion of chemotherapy.The minimum duration of
follow up for inclusion in study was 6 months.The details regarding anti
HBs titers at diagnosis and immunization given were obtained from the
case records.Based on the intial anti HBs titers childrenwere divided into 2
groups, those with protective anti HBs titers (> 10IU/L) and those with
non-protective titers (< 10IU/L).As per the divisions policy, all children
with protective anti HBs titers had received single booster of double dose
of Hepatitis B vaccine.Those with non-protective anti Hbs titers received
HBIG (20IU/Kg ;Max 400IU) followed by double dose of Hepatitis B vaccine
at 0,1,6 months starting 2 months after HBIG. AntiHBsAg titers were done
at follow up using Enzyme Linked Fluoroscent Assay method using VIDAS
(Bio-Merieux).
Results: Of the 104 children included in the study, 67 (64.4%) children had
protective anti HBs titers at presentation, whereas 37 (35.6%) had non-
protective titers. At follow up, 29 (27.8%) children had protective anti HBs
titers and 75 (72.2%) children had non-protective titers (<10 IU/L).Of the 67
children with protective antiHBstitres, 40.2% (n¼27) retained their pro-
tective titers, whereas 59.8% (n¼40) lost their protective titers.In the 37
children with non eprotective antiHBs titers at presentation only 5.4%
(n¼2) developed protective titers following passive and active immuni-
zation, whereas 96.4 % (n¼35) failed to seroconvert.
Discussion: Children receiving chemotherapy even with protective
antiHBs titers at presentation show a loss of protective titers, inspite of
receiving a single booster of double dose HBV vaccine.Those with non-
protective titers, failed to seroconvert despite a combination of passive and
active immunization .The loss of antiHBs titers occurred irrespective of the
levels of initial anti HBs titers larger sample size is required to statistically
validate these results
Conclusion: The loss of protective titers and the failure to seroconvert in
Acute Lymphoblastic Leukemia children receiving chemotherapy is a
concern especially in resource limited settings.The immunization as per this
schedule does not seem to offer protective titres against HBV.There is
probably a need formore frequentmonitoring of antiHBs titers and repeated
administration of Hepatitis B Immunoglobulin as passive prophylaxis which
in developing countries like ours is limited by ﬁnancial constraints.
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VORICONAZOLE PLASMA LEVELS, ITS DETERMINANTS, AND IMPACT ON
OUTCOME OF INVASIVE FUNGAL INFECTIONS IN CHILDREN WITH
CANCER: A PROSPECTIVE STUDY
Vasudeva Bhat, Shripad Banavali, Girish Chinnaswamy, Gaurav
Narula, Tushar Vora, Maya Prasad, Nikita Shah, Brijesh Arora. Tata
Memorial Hospital, Mumbai, IndiaBackground: We evaluated voriconazole plasma levels and determined
the impact of age, dose, route, generic formulations, and concomitant
drugs on plasma levels as well as impact of levels on outcome of invasive
fungal infections (IFI).
Methods: We prospectively studied 256 consecutive children (<19 years)
given voriconazole either for prophylaxis (N-154) or treatment (N-102) of
IFI between August 2008 and February 2016 as per the recommended
doses. IFI diagnosis and clinical outcome evaluation were based on EORTC
Mycoses Study Group (‘EORTC/MSG’) deﬁnitions. The therapeutic range
was deﬁned as 1e5 mg/ml.
Results: A total of 458 voriconazole trough measurements (median age 8
years) were analysed at steady-state [75 on intravenous (IV) and 181 on
oral (PO) doses]. Signiﬁcant Inter- and intrapatient variability in levels was
observed and 46% of patients required dose adjustment. The median vor-
iconazole dose was 16 mg/kg/day and the median duration of therapy was
6 weeks. 53% of children starting with the recommended dose achieved an
adequate trough level and 61% after therapeutic drug monitoring (TDM)-
based dose adjustments. A signiﬁcant correlation between oral doses and
trough levels of voriconazole was observed in patients less than 11 years
old (Spearman's rank correlation coefﬁcient ¼0.18, P < 0.03). A signiﬁcant
relationship was established between plasma levels above normal range
and liver toxicity (P¼0.03). On IV to oral switch, 25% children had drop in
the serum levels to subtherapeutic levels. No impact of gender, steroids
usage, and use of generic formulation was observed on levels or outcome.
Children with Voriconazole level <1 mg /ml were more likely to have
treatment failure at week 6 of voriconazole therapy compared to children
with >1mg/ml (failure, 20.4% vs. 2.1%; P <0.001).). 26% children with sub-
optimal trough levels at 12 hours post voriconazole showed optimal levels
at 8 hours suggesting early plasma clearance and need for frequent dosing.
Conclusions: Our study conﬁrms the large Inter- and intrapatient vari-
ability in voriconazole trough plasma levels particularly after enteral
dosing necessitating higher than recommended doses in young children,
and a trend to non-linear pharmacokinetics in older patients. A signiﬁcant
relationship between voriconazole trough >1 mg/mL and outcomes as well
as some adverse events was conﬁrmed justifying the TDM especially in
young children.
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REGULAR NUTRITIONAL ASSESSMENT OF CHILDREN WITH
MALIGNANCY: OBSERVATIONS OF A NUTRITIONIST DEDICATED TO A
PAEDIATRIC ONCOLOGY UNIT
Syed Anis Fathima, Nutritionist 1, Tarangini Durugappa 2, Anand
Prakash 2. 1Cuddles Foundation, India; 2Department of Paediatrics, Unit of
Hematology e Oncology, St John's Medical College Hospital, Bangalore, India
Abstract
Introduction: Nutritional status is recognised to be amodiﬁable risk factor
for treatment outcomes in Pediatric Oncology. In a developing country
Non- Governmental Organizations can play an important role in sup-
portive care. A Nutritionist supported by Cuddles foundation started
nutritional assessment and intervention at our centre from March 2016.
Objective: To determine the nutritional status in childrenwithmalignancy
at the start of therapy and on serial follow up by a nutritionist dedicated to
the Paediatric Oncology Unit.
Method: All children diagnosed with malignancy between March 2016
and August 2016 were included. Demographic details of children were
collected. Anthropometric indices (Weight, Height, BMI and Mid Upper
Arm Circumference) were recorded at serial time points (at diagnosis and
at follow up visits of 6 to 8 weeks). Counselling of appropriate diet and
enteral based formula feeding were the nutritional interventions. Changes
in nutritional status during this period were analysed.
Results: A total of 27 children were analysed including 15 Haemato-
lymphoid and 12 solid tumors. Mean age of children was 5.6yrs (9 months
to 16 yrs) of which 19 were males and 8 were females. Based on BMI,
21(77.5%) children started therapy with under nutrition including Mild
(-1to -2SD), Moderate (-2 to -3 SD), Severe (<-3SD)malnutrition in 7 (26%),
7 (26%) and 8 (30%) respectively. Two (7.5%) children were overweight at
the start of therapy. On follow up, 46% of children had improvement, 26.9%
were static and 26.9% had a worsening in nutritional status during their
follow up visits. Of 8 (29.6%) children who started with severe
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one child Stage IV Burkitt's lymphoma succumbed to sepsis.
Conclusion: A signiﬁcant proportion of children with malignancy in the
developing world start treatment with under nutrition. Childrenwith mild
and moderate malnutrition show improvement in nutritional status with
nutritionist intervention. Children with severe under nutrition at the start
of therapy continue to be a challenge in the developing world. Nutritional
assessment by nutritionist throughout therapy for malignancy is essential
for appropriate nutrition intervention.
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CYTOMEGALOVIRUS (CMV) VIRAEMIA AND DISEASE IN CHILDREN
WITH HAEMATOLOGICAL MALIGNANCIES UNDERGOING
CONVENTIONAL CHEMOTHERAPY: A LARGE STUDY FROM A REFERRAL
CANCER CENTRE IN INDIA
Subramaniam Ramanathan 1, Tushar Idhate 1, Seema Gulia 1, Sanjay
Biswas 2, Rohini Kelkar 2, Tushar Vora 1, Maya Prasad 1, Girish Chinnaswamy1,
Gaurav Narula 1, Brijesh Arora 1, Shripad Banavali 1. 1Department of Medical
Oncology (Pediatric), Tata Memorial Hospital, India; 2Department of
Microbiology, Tata Memorial Hospital, Mumbai, India
Background: There is paucity of data on CMV infection in haematological
malignancies in non-transplant settings, which is critical to plan timely
therapy and reduce morbidity and mortality.
Methods: Between January 2008 and November 2015, we screened all
children with haematolymphoid malignancies having unexplained fever,
prolonged cytopenia, hemophagocytic lymphohistiocytosis (HLH) or clin-
ical CMV disease, for CMV using RT-PCR. CMV-positive episodes were
analysed for clinical features and response to treatment.
Results: Seventy children had CMV infection. Of them, 61 (87%) had CMV
DNAemia and 9 (13%) had CMV disease. The primary diagnoses were ALL
(n¼59, 85%), AML (n¼2), NHL (n¼6), Hodgkin's lymphoma (HL, n¼2), and
CML (n¼1). The median age was 12 years. For ALL patients, CMV DNAemia
and disease occurred mostly during either consolidation (46%) or main-
tenance (36%) phase. The most common presenting feature of CMV
infection was unexplained fever without focus (n¼68, 97%). Of these, 37
(54.5%) had no associated cytopenias. All became afebrile at a median
ganciclovir duration of 3 days (range, 2-7 days). The rest (n¼31, 45.5%) had
unexplained fever with cytopenia, and all recovered after a variable period
of 3 to 28 days (median, 15 days). Two of them developed HLH and were
treated with HLH protocol along with antiviral therapy. For patients with
CMV viraemia, CMV titres became undetectable after amedian period of 17
days (range 7-34 days). Five had relapse of CMV-viraemia: two had com-
plete response and survived, while 3 died of primary malignancy during
CMV therapy. For the 9 with CMV disease, their primary diagnoses were
ALL (n¼6), AML (n¼1), HL (n¼1), and Burkitt's Lymphoma (n¼1). Disease
sites were chorioretinitis (n¼2), pneumonitis (n¼3), gastrointestinal dis-
ease (n¼2) and encephalitis (n¼1). In addition, one patient had both GI
infection and CMV encephalitis. After treatment with I.V. ganciclovir, 5
patients recovered fully, 2 died of CMV, one died of progressive primary
disease and one was lost to follow up. Out of the 2 children with cho-
rioretinitis, one had permanent visual deﬁcits while the other recovered
with normal vision.
Conclusion: CMV DNAemia and disease are common in children with
haematological malignancies on standard-dose therapy. ALL patients were
more commonly affected, usually during the consolidation phase of ALL
therapy. Most presented with unexplained fever with or without pro-
longed cytopenias. Approximately 15% can progress to HLH or CMV disease
if not detected in time. Timely detection and therapy with ganciclovir is
curative in most children.
TM_SC-1_V1.11
PROCEDURAL SEDATION IN PEDIATRIC ONCOLOGY e A RANDOMIZED
COMPARATIVE TRIAL OF KETAMINE e MIDAZOLAM COMBINATION VS
PROPOFOL
C. Varsha, Manas Kalra, Anita S. Bakshi, Geeta Mandhani, Amita
Mahajan. Apollo Center for Advanced Pediatrics, Indraprastha Apollo
Hospitals, Delhi, IndiaBackground: Procedural pain is a signiﬁcant quality of life issue in chil-
dren undergoing treatment for childhood cancer. Painful procedures are
therefore done under sedation wherever feasible. Ideal sedation should be
safe, effective, have prompt induction and smooth recovery. Both keta-
mine-midazolam and propofol are frequently used in this setting and have
been reported to be efﬁcacious. However, there are no published pro-
spective, randomized comparative trials (RCT) directly comparing these
two groups when performed by non- anesthesiologists.
Objective: To compare ketamine+midazolam (Group A) and propofol
(Group B) as sedative agents for intrathecal chemotherapy with regards to
efﬁcacy, side effect proﬁle, time to induction, time to recovery and
smoothness of recovery.
Methods: A partially-blinded, RCTwas conducted over a period of one year
between July 2015-July 2016 after institutional ethics committee approval.
Children aged 1-12 years requiring intravenous sedation for intrathecal
chemotherapy were included. Children with known cardiovascular or
respiratory disturbances, presence of neurological abnormalities and he-
patic/renal failure were excluded. Patients were allocated to the two
treatment arms using computer generated randomization tables after
obtaining written, informed consent. The initial doses used were, keta-
mine at 2mg/kg, midazolam at 0.2 mg/kg and propofol at 2.5mg/kg as per
standard recommendations. The patient, parents and the person analyzing
the data were blinded. Time to sedation, dose required for effective
sedation, depth of sedation (using Modiﬁed Ramsey scale), vital parame-
ters intra-procedure, time to recovery, smoothness of recovery and
emergence phenomenon were documented.
Results: One hundred and ﬁve patients were enrolled (Group A: 53, Group
B: 52). Seven patients had failure of sedation (all were in Group B). 9 pa-
tients in group A and 35 patients in group B required top up over and above
the initial administered doses. Mean time to sedation in group B was
shorter than in group A (p¼0.001).Mean heart rate in group A was higher
than in group B (p¼0.000). Transient drop in saturation was noted in 9
patients in group A and in 14 patients in group B. Mean depth of sedation
in group A was greater than in group B (p¼0.001). Mean time to recovery
in group B was shorter than in group A (p¼0.000). Emergence symptoms
were experienced by 29 patients in group A and 5 patients in group B
(p¼0.000)
Conclusion: Ketamine-Midazolam combination appears to be safer and
more effective. However, propofol has a signiﬁcantly faster onset, quicker
recovery with a smoother emergence from sedation, but at the recom-
mended initial doses it provides inadequate sedation.
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AN AUDIT OF CENTRAL VENOUS ACCESS DEVICES (CVADS) IN PEDIATRIC
ONCOLOGY
Deepankar Bhattacharya, Shalini Mishra, Sandeep Jain, Gauri Kapoor. Rajiv
Gandhi Cancer Institute and Research Centre, New Delhi, India
Background: Central Venous access devices (CVADs) usage comprises an
integral component for management of childhood malignancies. The
purpose of this study was to evaluate our experience of CVADs with regard
to their feasibility, safety, and complications.
Material andmethods: A retrospective analysis of all CVADs [peripherally
inserted central catheter (PICCs), chemoports (port-a-cath) and Hickman
catheters]placed in Pediatric Oncology department of our institute from
June 2015 to May 2016, was done. All procedures were performed under
ultrasound guidance ± image intensiﬁer. Information was collected
regarding demographic details, catheter life (number of catheter days), and
adverse events (AE) [namelyinfection, blockage, extrusion, port-tip
migration and exit site skin excoriation]. Risk factors for AE were analysed
which included underlying disease, age of patient, type of CVAD and
number of catheter days.
Results: During the study interval, 147 CVADs were placed in 138 patients
with a median age of 7.5 years (range 10 months -18 years) and a male:
female ratio of 100:38. The CVADs included 117 PICCs, 23 chemoports and
7 Hickman catheters. Three patients who came only for PICC insertion
were excluded from analysis. The remaining 135 patients had a follow-up
of 151 median catheter days (range 8 e 375 days). Overall incidence of AE
was 0.828/1000 catheter days (19/22,924 catheter days).None of the
